Astria Therapeutics, Inc.
ATXS
$13.14
$0.050.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -23.98% | -25.40% | -32.35% | -29.32% | -82.75% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 56.74% | 37.92% | 20.41% | 24.00% | 64.00% |
| Change in Net Operating Assets | -261.65% | -311.42% | 708.33% | 288.27% | -431.40% |
| Cash from Operations | -27.26% | -43.57% | -29.41% | -18.65% | -92.52% |
| Capital Expenditure | -73.02% | -87.69% | -1,525.00% | -1,200.00% | -752.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 171.49% | 145.74% | 80.27% | -241.80% | -9,945.49% |
| Cash from Investing | 171.05% | 145.35% | 80.10% | -242.07% | -10,172.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -93.35% | -93.31% | 77.83% | 102.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -93.35% | -93.31% | 77.83% | 102.94% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 139.37% | 76.35% | -288.89% | -174.75% | -152.92% |